Tesaro (TSRO) PT Raised to $128 at RBC Capital

October 10, 2016 7:27 AM EDT
Get Alerts TSRO Hot Sheet
Price: $116.00 +0.76%

Rating Summary:
    14 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade TSRO Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

RBC Capital analyst Adnan Butt reiterated an Outperform rating and raised its price target on Tesaro (NASDAQ: TSRO) to $128.00 (from $122.00) following NOVA Phase 3 trial details.

Butt commented, "Details show biomarker/HRD-positive benefit is not driven by somatic BRCA patients alone, biomarker/HRD-negative population shows a stat sig benefit, which allows TSRO to file broadly for platinum sensitive ovarian cancer patients, the broadest addressable market and an upside scenario, and safety/tolerability differences could point to further PARP inhibitor separation. Niraparib is the PARP inhibitor to beat and there is no legitimate competitive threat near-term. PT to $128 from $122."

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $99.26 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

RBC Capital

Add Your Comment